In This Article:
Medtronic recently saw a substantial price movement, climbing 10% over the last quarter. This period was marked by the release of promising five-year data from the Evolut Low Risk Trial, which indicated favorable outcomes for the company's transcatheter aortic valve replacement system compared to surgery. Further boosting investor sentiment was the FDA approval of Medtronic's BrainSense technology, enhancing treatment for Parkinson's disease. Despite challenging overall market conditions, with significant declines in key indexes such as the S&P 500 and Nasdaq, Medtronic's substantial product advancements likely contributed to the positive performance of its shares amidst broader downward trends.
Buy, Hold or Sell Medtronic? View our complete analysis and fair value estimate and you decide.
Over the past five years, Medtronic has delivered a total shareholder return of 7.52%. While this performance marks a modest increase, it underperforms both the broader U.S. market and the medical equipment industry over the last year, where market returns were 5.8% and industry returns were 2.4%, respectively. Several key developments likely influenced Medtronic’s share price trajectory during this period. The announcement of the global observational study DISSECT-N in June 2020 and the FDA approval for the Percept PC Deep Brain Stimulation system marked significant milestones. Furthermore, the launch and European release of the Evolut TAVR system in mid-2020 demonstrated Medtronic’s continued commitment to innovation.
The company's consistent dividend payouts bolstered investor confidence, with recent approvals maintaining shareholder value. Additionally, the approval and expansion of Medtronic's Renal Denervation technique and the ongoing development of the Hugo soft tissue robotic platform have shaped its growth narrative, targeting increased market share and revenue expansion, particularly in emerging markets. However, challenges such as competitive pressures and regulatory hurdles may have constrained faster growth in the valuation metrics. Collectively, these factors provide context to Medtronic's overall market performance over the past five years.